Indoco Remedies’ Baddi facility receives UK MHRA approval

Pharmaceutical company Indoco Remedies Ltd said that its solid dosages facility at Baddi, Himachal Pradesh received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) after a regulatory inspection.

The inspection was carried out from October 16-18, 2018, Indoco said.

Spread over an area of 18,000 square metre, Indoco’s solid dosages facility at Baddi manufactures tablets, cream, ointment, liquid orals and toothpaste.

It has a manufacturing capacity of 4.3 billion tablets and 50 million capsules per annum.

This was also the first regulatory inspection for the plant since its acquisition in 2016.

“The outcome of this inspection is positive and is a testimony that Indoco maintains global quality standards and follows strict Good Manufacturing Practice (GMP) guidelines. The facility will cater mainly to the European markets”, said Aditi Panandikar, Managing Director, Indoco Remedies Ltd.

Headquartered in Mumbai, Indoco Remedies Ltd is a fully integrated, research-oriented pharma company with presence in 55 countries.

The company has 9 manufacturing facilities in Goa, Baddi and Waluj. It develops and manufactures a wide range of pharmaceutical products for the Indian and international markets and generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties.

Indoco has nine domestic marketing divisions in various therapeutic segments including respiratory, anti-infective, dental Care, pain management, gastrointestinal, ophthalmic, cardiovascular, anti-diabetics and anti-obesity.

Top Indoco brands include, Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G,Sensoform, Sensodent-KF, Karvol Plus,Glychek and Tuspel Plus. On the international front, it has tie-ups with large generic companies like Actavis in USA and ASPEN in South Africa.